伴随式诊断的共同研究及授权契约:2010年～2025年

"伴随诊断合作与许可交易" 报告提供了对全球领先生物製药公司达成的伴随诊断交易的全面了解和前所未有的访问管道。

本报告详细介绍了2010年至2025年期间的伴随诊断交易，并详细分析了公司达成伴随诊断交易的方式和原因。这些交易通常包含多个组成部分，从合作研发到成果商业化。

本报告涵盖了合作、开发、研究和授权交易。

本报告全面列出了自2010年以来宣布的545项伴随诊断交易。此外，报告还包含本公司及其合作伙伴向美国证券交易委员会提交的合约文件（如有）。

本报告的第一章介绍了伴随诊断交易。

第1章为报告简介。

第2章概述了自2010年以来伴随诊断领域的交易活动。

第3章概述了自2010年以来的主要伴随诊断交易。交易按交易金额列出。

第4章简要概述了伴随诊断交易中最活跃的25家公司，随后提供了伴随诊断交易的完整清单以及公开的交易文件。

第5章全面深入地回顾了自2010年1月以来宣布的所有伴随诊断交易，并提供了公开的交易文件。

第6章全面深入地回顾了自2010年1月以来达成或宣布的伴随诊断伙伴关係。本章按伴随诊断技术类型组织。

本报告也包含大量图表和数据，展现了自2010年以来伴随诊断交易的趋势和活动。

此外，报告还提供了一个全面的交易目录，按公司A-Z、交易类型和治疗目标进行整理。每个交易标题都透过网页连结连结到线上交易记录，方便使用者根据需要轻鬆存取每份交易文件（如有）。

主要的优点

"伴随诊断中的合作与授权协议" 提供读者以下主要优势：

• 了解自2010年以来的交易趋势
• 浏览伴随诊断的共同开发与授权交易
• 基准分析 - 确定交易的市场价值
• 财务条款 - 一次性付款、里程碑付款、特许权使用费
• 依公司A-Z、交易类型及治疗领域排列的交易目录
• 主要交易价值
• 最活跃的交易撮合者
• 确定每笔交易的资产和交易条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款是否适合您的合作伙伴
• 节省数百小时的研究时间

调查范围

• 合作与 "伴随诊断许可协议" （ "伴随诊断合作与许可协议" ）旨在深入了解全球领先生物製药公司达成的伴随诊断趋势和交易结构。

伴随诊断合作与授权协议包括：

• 生物製药产业伴随诊断交易趋势
• 涵盖製药和生物技术的伴随诊断交易记录目录
• 伴随诊断领域的主要交易
• 最活跃的伴随诊断许可公司
• "伴随诊断合作与许可协议" 提供全面的交易记录存取权限，包括合约文件（如有）。

分析合约有助于进行尽职调查：

• 授予或选择的具体权利是什么？
• 合约伙伴实际上被授予了什么？
• 授予了哪些独家权利？
• 合约的付款结构是怎样的？
• 如何审计销售和付款？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 如何处理和归属知识产权？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密和资讯揭露？
• 如何解决争议？
• 在什么情况下可以终止合约？
• 如果所有权发生变更会发生什么事？
• 已约定哪些分许可或分包条款？
• 公司坚持哪些样板条款？
• 哪些样板条款似乎因合作伙伴和交易类型而异？
• 该公司在合约法方面主张哪个司法管辖权？

目录

摘要整理

第1章 简介

第2章 伴随式诊断的交易趋势

• 简介
• 多年的伴随式诊断交易
• 最活跃的伴随式诊断交易业者
• 伴随式诊断交易，各交易类型
• 伴随式诊断交易，各治疗领域
• 伴随式诊断交易，各业界
• 伴随式诊断交易的交易条件
  • 伴随式诊断交易的主要价值
  • 伴随式诊断契约的预付款
  • 伴随式诊断交易的里程金
  • 伴随式诊断的权利金费率

第3章 -主要伴随式诊断交易

• 简介
• 主要的伴随式诊断交易，各金额

第4章 -最活跃的伴随式诊断的交易厂商

• 简介
• 最活跃的伴随式诊断交易业者
• 最活跃的伴随式诊断交易的企业简介

第5章 伴随式诊断契约交易名录

• 简介
• 伴随式诊断契约交易名录

第6章 -各技术类型的伴随式诊断交易

• 交易名录
• 交易名录- 伴随式诊断交易，各企业
• 交易名录- 伴随式诊断交易，各交易类型
• 交易名录- 伴随式诊断交易，各治疗领域
• 交易类型定义
• 关于调查公司
• 目前联盟
• 目前契约
• 最近的报告标题

Companion Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the companion diagnostic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of companion diagnostic deals from 2010 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 545 companion diagnostic deals announced since 2010 including financial terms where available including links to online deal records of actual companion diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of companion diagnostic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2010.

Chapter 3 provides an overview of the leading companion diagnostic deals since 2010. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in companion diagnostic dealmaking with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of companion diagnostic deals signed and announced since Jan 2010, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of companion diagnostic partnering deals signed and announced since Jan 2010. The chapter is organized by specific companion diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in companion diagnostic deal making since 2010.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Companion Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2010
• Browse companion diagnostic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Companion Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of companion diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Companion Diagnostic Collaboration and Licensing Deals includes:

• Trends in companion diagnostic dealmaking in the biopharma industry
• Directory of companion diagnostic deal records covering pharmaceutical and biotechnology
• The leading companion diagnostic deals by value
• Most active companion diagnostic licensing dealmakers
• Companion Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in companion diagnostic dealmaking

• 2.1. Introduction
• 2.2. Companion diagnostic deals over the years
• 2.3. Most active companion diagnostic dealmakers
• 2.4. Companion diagnostic deals by deal type
• 2.5. Companion diagnostic deals by therapy area
• 2.6. Companion diagnostic deals by industry sector
• 2.7. Deal terms for companion diagnostic deals
  • 2.7.1 Companion diagnostic deals headline values
  • 2.7.2 Companion diagnostic deal upfront payments
  • 2.7.3 Companion diagnostic deal milestone payments
  • 2.7.4 Companion diagnostic royalty rates

Chapter 3 - Leading companion diagnostic deals

• 3.1. Introduction
• 3.2. Top companion diagnostic deals by value

Chapter 4 - Most active companion diagnostic dealmakers

• 4.1. Introduction
• 4.2. Most active companion diagnostic dealmakers
• 4.3. Most active companion diagnostic deals company profiles

Chapter 5 - Companion diagnostic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Companion diagnostic contracts dealmaking directory

Chapter 6 - Companion diagnostic dealmaking by technology type

• Deal directory
• Deal directory - Companion diagnostic deals by company A-Z
• Deal directory - Companion diagnostic deals by deal type
• Deal directory - Companion diagnostic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Companion diagnostic deals since 2016
• Figure 2: Active companion diagnostic dealmaking activity - 2016 - 2025
• Figure 3: Companion diagnostic deals by deal type since 2016
• Figure 4: Companion diagnostic deals by therapy area since 2016
• Figure 5: Companion diagnostic deals by industry sector since 2016
• Figure 6: Companion diagnostic deals with a headline value
• Figure 7: Companion diagnostic deals with an upfront value
• Figure 8: Companion diagnostic deals with a milestone value
• Figure 9: Companion diagnostic deals with a royalty rate value
• Figure 10: Top companion diagnostic deals by value since 2016
• Figure 11: Most active companion diagnostic dealmakers 2016 - 2025
• Figure 12: Companion diagnostic deals by technology type since 2016